About
LIBI Diagnostics is a gene-biomarker start-up for the early detection of cancer, powered by next-generation bio-liquid tests.
Using state-of-the-art Next-Generation Sequencing (NGS) technology, LIBI-Diagnostics customizing tests for each patient by detecting alterations of Aurora Kinase A in blood and/or voided urine samples compared to the genomic expression data in the primary tumor.
Libi-Diagnostics provides a practical and effective answer to the the inefficiency of periodic imaging tests. LIBI diagnoses recurrent cancerous development in an early stage with only few cells and provides sufficient information to neutralize that early development. In this way, it is possible to spare the patient aggressive treatments, unnecessary suffering and maintain his good chances of survival.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is LIBI-Diagnostics' primary focus?
- LIBI-Diagnostics is a gene-biomarker startup focused on the early detection of cancer using next-generation bio-liquid tests.
- When was LIBI-Diagnostics founded?
- LIBI-Diagnostics was founded in January 2020.
- Where is LIBI-Diagnostics headquartered?
- LIBI-Diagnostics is headquartered in Haifa, Israel.
- What technology does LIBI-Diagnostics use for its cancer detection tests?
- LIBI-Diagnostics uses Next-Generation Sequencing (NGS) technology to detect alterations of Aurora Kinase A in blood and/or urine samples.
- What is the current employee count for LIBI-Diagnostics?
- LIBI-Diagnostics currently has 6 employees.
- Has LIBI-Diagnostics raised any funding?
- Yes, LIBI-Diagnostics completed a Crowdfunding round in October 2021, with Headstart as a lead investor. For full financing history, please refer to startupim.
- What is LIBI-Diagnostics' current product stage?
- LIBI-Diagnostics' product is currently in the R&D stage.
- Who are the founders of LIBI-Diagnostics?
- The founders of LIBI-Diagnostics are David Risin and Dr. Ayelet Ben Barak.